Dr. Mirza Discusses Niraparib Dose Modifications for Patients With Low Body Weight

Mansoor Raza Mirza, MD
Published: Sunday, Mar 25, 2018


Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses a study of safety and dose modification for patients with low body weight receiving niraparib (Zejula) in the ENGOT-OV16/NOVA phase III trial during the 2018 Society of Gynecologic Oncology Annual Meeting.

Results of this retrospective analysis showed patients who had <77 kg body weight and/or <150,000/µL platelet counts had a greater risk of grade 3 or 4 thrombocytopenia, compared to patients who were heavier and had higher platelets counts, Mirza says.

Interestingly, the patients with lower body weight and platelet counts were able to remain on the 300-mg starting dose of niraparib. Only 3% of patients on the study discontinued treatment due to thrombocytopenia.

These data suggest that niraparib is very manageable, dose adjustments can allow patients to remain on the drug for a long time, and lower doses likely have the same efficacy as the 300-mg dose, Mirza explains.

 

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses a study of safety and dose modification for patients with low body weight receiving niraparib (Zejula) in the ENGOT-OV16/NOVA phase III trial during the 2018 Society of Gynecologic Oncology Annual Meeting.

Results of this retrospective analysis showed patients who had <77 kg body weight and/or <150,000/µL platelet counts had a greater risk of grade 3 or 4 thrombocytopenia, compared to patients who were heavier and had higher platelets counts, Mirza says.

Interestingly, the patients with lower body weight and platelet counts were able to remain on the 300-mg starting dose of niraparib. Only 3% of patients on the study discontinued treatment due to thrombocytopenia.

These data suggest that niraparib is very manageable, dose adjustments can allow patients to remain on the drug for a long time, and lower doses likely have the same efficacy as the 300-mg dose, Mirza explains.

 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x